BioSpace News Archive

Ardelyx said doses of tenapanor, which inhibits controls serum phosphorus by inhibiting the sodium hydrogen exchanger 3 (NHE3), demonstrated a statistically significant reduction in serum phosphorus levels for dialysis patients whose hyperphosphatemia was not previously controlled with phosphate binders alone.

Getting life scientist jobs can be your best decision ever. Why? It offers endless opportunities, job satisfaction, security, and competitive pay and much more.

Companies from across Europe and Asia share updates on their business and pipelines.

Esperion announced that, on August 27, 2019, the Compensation Committee of Esperion’s Board of Directors granted non-qualified stock options to purchase an aggregate of 39,500 shares of its common stock and 35,388 restricted stock units to eighteen new colleagues under Esperion’s 2017 Inducement Equity Incentive Plan.

A fully integrated biopharmaceutical company - Uni-Bio Science Group Limited are pleased to announce that its interim results for the period ended 30 June 2019

Citing unnamed sources “familiar with the matter,” Reuters said that the company will have no choice but to file for bankruptcy should a settlement not be agreed upon.

Bristol-Myers will become a limited partner, investing in projects of mutual interest, with an option to buy the companies once there is a preclinical candidate.

In the BioSpace poll, 55.17% of respondents said, Yes, companies should be allowed to sue competitors to prevent generic versions of their drugs, and 41.38% said no. A much smaller group, 3.45%, said they were unsure.

The company indicates there was “a trend toward less bleeding with edoxaban, though, results did not show statistical superiority.”

Apogenix announced that a new publication in Cancer Management and Research[1] reviews asunercept as a promising treatment option for patients with other malignancies beyond glioblastoma and myelodysplastic syndromes.